Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

Publisher Name :
Date: 05-Apr-2017
No. of pages: 70
Price : Single User: US $ 3500  US $ 2500 Corporate User: US $ 5000  US $ 4000
Inquire Before Buying
Avail $1000 Discount on this report till 31 August 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.

The analysts forecast global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.

Covered in this report

This report covers the present scenario and the growth prospects of the global hypertrophic cardiomyopathy therapeutics market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • AstraZeneca

  • Merck

  • Pfizer

  • Sanofi


Other prominent vendors


  • Gilead Sciences

  • Novartis

  • Teva Pharmaceutical Industries


Market driver


  • Adoption of sedentary lifestyle.

  • For a full, detailed list, view our report


Market challenge


  • Technological advances in devices.

  • For a full, detailed list, view our report


Market trend


  • Development of translational bioinformatics (TBI).

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2021 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Avail $1000 Discount on this report till 31 August 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Disease overview

PART 06: Key clinical trials

PART 07: Market dynamics

PART 08: Market landscape
Market overview
Five forces analysis

PART 09: Market segmentation by drug-class
Global calcium channel blockers market
Global beta-adrenergic blockers market
Global antiarrhythmic market
Global anticoagulants market

PART 10: Geographical segmentation
HCM therapeutics market in Americas
HCM therapeutics market in EMEA
HCM therapeutics market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges
Market drivers
Market challenges
Impact of drivers and challenges on key customer segments (hospitals and pharmacies)

PART 13: Market trends
Increasing availability of genetic tests
Development of TBI
Advent of genomic medicine

PART 14: Vendor landscape
Competitive landscape

PART 15: Key vendor analysis
AstraZeneca
Merck
Pfizer
Sanofi
Other prominent vendors

PART 16: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Types of HCM
Exhibit 02: Treatment for HCM
Exhibit 03: Snapshot of HCM therapeutics pipeline 2016
Exhibit 04: Pipeline analysis for HCM therapeutics market
Exhibit 05: Mutation
Exhibit 06: Identification of pathogenicity in genes by genetic testing
Exhibit 07: Global HCM therapeutics market snapshot
Exhibit 08: Global HCM therapeutics market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis in global HCM therapeutics market
Exhibit 10: Five forces analysis
Exhibit 11: Market segmentation based on drug class
Exhibit 12: Global calcium channel blockers market 2016-2021 ($ millions)
Exhibit 13: Global beta-adrenergic blockers market 2016-2021 ($ millions)
Exhibit 14: Global antiarrhythmic market 2016-2021 ($ millions)
Exhibit 15: Global anticoagulants market 2016-2021 ($ millions)
Exhibit 16: Global HCM therapeutics market by geography 2016 and 2021
Exhibit 17: Global HCM therapeutics market by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: HCM therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: HCM therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: HCM therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 24: Prevalence of obesity among US adults 2015
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Group of HCM individuals based on genetic tests
Exhibit 27: Competitive structure analysis of global HCM therapeutics market 2016
Exhibit 28: AstraZeneca: Key highlights
Exhibit 29: AstraZeneca: Strength assessment
Exhibit 30: AstraZeneca: Strategy assessment
Exhibit 31: AstraZeneca: Opportunity assessment
Exhibit 32: Merck: Key highlights
Exhibit 33: Merck: Strength assessment
Exhibit 34: Merck: Strategy assessment
Exhibit 35: Merck: Opportunity assessment
Exhibit 36: Pfizer: Key highlights
Exhibit 37: Pfizer: Strength assessment
Exhibit 38: Pfizer: Strategy assessment
Exhibit 39: Pfizer: Opportunity assessment
Exhibit 40: Sanofi: Key highlights
Exhibit 41: Sanofi: Strength assessment
Exhibit 42: Sanofi: Strategy assessment
Exhibit 43: Sanofi: Opportunity assessment

  • United States Peptide Therapeutics Market Report 2017
    Published: 18-Aug-2017        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rat......
  • United States Hypertrophic Cardiomyopathy Therapeutics Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market ......
  • Raynauds Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 48
    Raynauds Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Raynauds Disease - Pipeline Review, H2 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape. Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smok......
  • Batten Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 53
    Batten Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H2 2017, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually......
  • Trigeminal Neuralgia - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 54
    Trigeminal Neuralgia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H2 2017, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain o......
  • Visceral Pain - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 55
    Visceral Pain - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2017, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape. Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pai......
  • Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 119
    Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important c......
  • Liver Cirrhosis - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 90
    Liver Cirrhosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver wh......
  • Global Peptide Therapeutics Sales Market Report 2017
    Published: 14-Aug-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Peptide Therapeutics for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs